Table I.

Clinical trials in this pooled analysis.

Authors/(ref.)	N	Regimen
Elliott, et al (19)	48	Etoposide 130 mg/m2/day intravenously × 3 days + cisplatin 45 mg/m2/day intravenously days 2 and 3 (cycle length = 28 days)
Rubin, et al (20)	42	5-fluorouracil 425 mg/m2 intravenously days 1–5 + leucovorin 20 mg/m2 intravenously days 1–5 (cycle length = 28 days)
Burch, et al (21)	44	5-fluorouracil 450 mg/m2 intravenously days 1–5 + levamisole 100 mg/m2 orally 3 times a day, days 1–3 and 50 mg/m2 orally 3 times a day on days 4 and 5 (cycle length = 35 days)
Erlichman, et al (22)	68	Irinotecan 260–320 mg/m2 intravenously on day 1 (cycle length = 21 days)
Jatoi, et al (23)	46	Docetaxel 50 mg/m2 intravenously on day 1 + irinotecan 130 mg/m2 intravenously on day 1 (cycle length 21 days)
Jatoi, et al (24)	43	Oxaliplatin 130 mg/m2 intravenously on day 1 + capecitabine 850–1000 mg/m2 orally twice a day × 14 days (cycle length = 21 days)
Giordano, et al (25)	44	Docetaxel 75 mg/m2 intravenously on day 1 + capecitabine 825 mg/m2 orally twice a day on days 1–14 (cycle length = 21 days)
Jatoi, et al (26)	35	Bortezomib 1.2 mg/m2 intravenously on days 1, 4 and 8 + paclitaxel 175 mg/m2 intravenously on day 2 + carboplatin area under the curve of 2 intravenously on day 2 (cycle length = 21 days)